Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.35 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072237 | 0.83 | POLB (0.51) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL23840972 | 0.82 | PPARG (0.40) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL5932825 | 0.81 | KMT2A (0.43) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL5933473 | 0.77 | PPARG (0.46) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL5933468 | 0.77 | KMT2A (0.43) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL21553193 | 0.77 | PPARG (0.46) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL4056199 | 0.76 | PPARG (0.42) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL9328044 | 0.76 | PPARG (0.42) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL5932833 | 0.76 | PPARG (0.42) | HTR2APPARGPPARAPOLBCA1 | |
| SCHEMBL9328050 | 0.76 | KMT2A (0.46) | HTR2APPARGPPARAPOLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | OLIPASS CORPORATION (KR) | 2019-11-07 | — | — | US | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | HTR2A 1606/4885PPARG 206/4885PPARA 142/4885 |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | PTBP1, RBM17, UPF1 | HTR2A 4665/4885PPARG 2473/4885PPARA 1687/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | HTR2A 2578/4885PPARG 4485/4885PPARA 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.